News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
94
Sources here
15
Companies here
7
Search results Stored financial headlines

Active search

94 matching headlines

Ticker or company: ENWMain company stories
Clear
Latest

MarketBeat Earnings

Aureus Greenway (NASDAQ:PUSA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Aureus Greenway (NASDAQ:PUSA) from a "sell" to a "hold" rating, though MarketBeat's overall average rating remains "Sell." The company's shares recently rose 4.9%, opening at $3.64, despite reporting breakeven EPS, negative net margin, and negative return on equity. Several institutional investors, including State Street and Geode Capital Management, have increased their holdings in …

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Aureus Greenway Holdings Inc Q2 2026: Revenue $708458 EPS $(0.001) — 10-Q Summary

Aureus Greenway Holdings Inc. reported its Q2 2026 results, showing revenue of $708,458, a 17.6% increase year-over-year, and a significantly narrowed net loss of $39,262. Diluted loss per share improved to $(0.001) from $(0.021) in the prior year. The revenue growth was attributed to …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aureus Greenway (PUSA) grows golf revenue but posts larger loss and major merger

Aureus Greenway Holdings Inc. (PUSA) reported an increase in golf-related revenue to $2.18 million for the first half of 2026, up from $1.93 million a year prior, primarily due to higher green fees and merchandise sales. However, the company's net loss significantly widened to …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aureus Greenway Holdings Inc SEC Filing (Aug 13, 2026)

Aureus Greenway Holdings Inc. announced the effectiveness of its S-4 filing on August 12, 2026, with the SEC accepting it on August 13, 2026. The filing indicates a neutral impact and sentiment according to AI analysis. The company, trading under NASDAQ: PUSA, is ranked …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aureus Greenway Holdings Ord Shs (PUSA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Aureus Greenway Holdings Ord Shs (PUSA), focusing on future EPS and revenue growth estimates. It includes current stock data, market capitalization, and a peer comparison with other companies in the Hotels & Entertainment Services sector. The financial …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Powerus, Aureus Greenway Holdings Inc. announce $2.51M purchase order for drones in support of Department of War program

Powerus, through its subsidiary Tandem Defense, has secured a $2.51 million purchase order from a defense prime contractor for 1,500 U.S.-made FPV aircraft and related equipment, intended for a Department of War program. This announcement was made jointly with Aureus Greenway Holdings Inc. (AGH), …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Powerus schedules 1,500 U.S.-made FPV drones for delivery in 60 days

Powerus, through its subsidiary Tandem Defense, has received a $2.51 million purchase order from a Department of War prime contractor for 1,500 U.S.-made FPV aircraft, 100 pilot kits, and 750 spare parts kits, with delivery scheduled within 60 days. This order supports the strategic …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences (NASDAQ:GLSI) Posts Quarterly Earnings Results

Greenwich LifeSciences (NASDAQ:GLSI) announced its quarterly earnings, reporting a loss of $0.27 per share, which exceeded analyst expectations of a $0.33 loss. The company's stock traded around $15.55, significantly below its 12-month high, with a market capitalization of approximately $228 million. Despite mixed analyst …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences 2Q 2026: Revenue $0 Net loss $(3.95M), EPS $(0.27) — 10-Q Summary

Greenwich LifeSciences (GLSI) reported no product revenue for Q2 2026, consistent with the prior year. The company posted a net loss of $(3.95M), or $(0.27) per diluted share, a slight improvement in EPS compared to the $(0.28) loss in Q2 2025. Key activities include …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Donald Smith & Co. (GNW) discloses 22.48M Genworth shares under management

Donald Smith & Co., Inc., along with DSCO Value Fund, L.P., has reported a beneficial ownership of 22,482,191 shares of Genworth Financial Inc. common stock, which accounts for 5.87% of the total class. Donald Smith & Co., Inc. holds sole voting power over 21,777,866 …

GNW main company
Sharemaestro market context Trend signal active 52 weeks +17.1% GNW stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced an extension of the lock-up period for shares owned by its directors, officers, and pre-IPO investors until January 31, 2027. This decision aims to support strategic and financing transactions, particularly as the company progresses with its Phase …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027

Greenwich LifeSciences has extended the lock-up period for shares held by its directors, officers, and pre-IPO investors until January 31, 2027. This decision, announced by the Board of Directors, signifies confidence in the company's long-term strategy and ongoing Phase III clinical trial for GLSI-100, …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences Directors, Officers Face 100% Lock-Up to 2027

Greenwich LifeSciences (GLSI) announced an extension of the lock-up period for shares held by its directors, officers, and pre-IPO investors until January 31, 2027. This move, which restricts stock sales unless modified by the Board, is accompanied by positive clinical trial updates for their …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aureus Greenway Holdings (PUSA) plans transformative merger with defense-tech firm Powerus

Aureus Greenway Holdings (PUSA) is pursuing a stock-for-stock merger with Autonomous Power Corporation (Powerus), creating "Powerus Corporation." Powerus stockholders are expected to own about 83.3% of the new company's common stock and 92.5% of voting power, with existing AGH stockholders holding 16.7%. The merger, …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genworth Financial Q2 Earnings Call Highlights

Key Points Interested in Genworth Financial, Inc.? Here are five stocks we like better. Enact led Genworth's second-quarter performance, contributing $143 million in adjusted operating income and returning $103 million of capital. Genworth raised its 2026 expected Enact capital-return range to $445 million–$485 million. …

GNW main company
Sharemaestro market context Trend signal active 52 weeks +17.1% GNW stored weekly price path from 22 Aug 2025 to 14 Aug 2026

$Aureus Greenway (PUSA.US)$ Today's gains

The article highlights the daily gains of Aureus Greenway (PUSA.US) stock. It's a short post within the Moomoo community, shared by a user named 老牛哥, focusing purely on the stock's performance for the day. The content is primarily a user-generated post and includes disclaimers …

PUSA main company
Sharemaestro market context Price below Trend Line 52 weeks +1.1% PUSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences (GLSI) Expected to Post Earnings on Thursday

Greenwich LifeSciences (GLSI) is projected to announce its Q2 2026 earnings before market open on Thursday, August 13th, with analysts anticipating a loss of $0.33 per share. The company's stock currently trades at $14.39, significantly below its 52-week high, and has a market capitalization …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genworth Financial, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:GNW) 2026-08-06

Key Points Interested in Genworth Financial, Inc.? Here are five stocks we like better. Enact led Genworth's second-quarter performance, contributing $143 million in adjusted operating income and returning $103 million of capital. Genworth raised its 2026 expected Enact capital-return range to $445 million–$485 million. …

GNW main company
Sharemaestro market context Trend signal active 52 weeks +17.1% GNW stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context